MedicaNatumin AB (publ) said its third-quarter normalized net income was 1.1 million kronor, an increase from 375,000 kronor in the prior-year period.
Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.
The normalized profit margin climbed to 5.2% from 1.6% in the year-earlier period.
Total revenue fell 12.3% on an annual basis to 20.6 million kronor from 23.5 million kronor, and total operating expenses fell 12.2% year over year to 20.2 million kronor from 23.0 million kronor.
Reported net income grew from the prior-year period to 1.6 million kronor, or 1 öre per share, from 200,000 kronor, or 0 öre per share.
As of Nov. 17, US$1 was equivalent to 8.75 Swedish kronor.